The convergence of rising autonomous vehicle development and the growing trend toward connected cars fuel a significant demand for automotive AI chipsets. This report, A Comprehensive Analysis of the Automotive AI Chipset Ecosystem, 2034, presents a comprehensive view of this dynamic market, highlighting lucrative opportunities for industry stakeholders. NEWARK, Del., Dec. 7, 2023 /PRNewswire/ —… Continue reading The passenger Vehicle Segment is expected to constitute a share of 72.0% in the Automotive AI Chipset Market in 2024 | Future Market Insights, Inc.
Category: Newswire
NWTN Announces Strategic Partnership with China State Construction Engineering Corporation (Middle East)
DUBAi, UAE, Dec. 7, 2023 /PRNewswire/ — NWTN Inc. (Nasdaq: NWTN), an eco-conscious mobility technology company bringing passenger-centric green premium mobility solutions to the world (“NWTN” or the “Company”), is thrilled to announce a landmark Memorandum of Understanding (MOU) with China State Construction Engineering Corporation (Middle East) LLC (CSCEC), marking a significant stride in international cooperation… Continue reading NWTN Announces Strategic Partnership with China State Construction Engineering Corporation (Middle East)
RewirEd Summit faz história na COP28 ao trazer a educação à vanguarda da ação climática para impactar bilhões de crianças e jovens ao redor do mundo
DUBAI, EAU, 9 de dezembro de 2023 /PRNewswire/ — RewirEd Summit, o primeiro encontro de cúpula mundial de educação sobre o clima reuniu 1.000 participantes, incluindo 2 chefes de estado, 22 ministros e 28 diretores executivos, com 260 palestrantes de diversos setores, representando 209 entidades e 76 países, para enfocar lacunas urgentes na transformação da… Continue reading RewirEd Summit faz história na COP28 ao trazer a educação à vanguarda da ação climática para impactar bilhões de crianças e jovens ao redor do mundo
InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets
HAUPPAUGE, N.Y., Dec. 9, 2023 /PRNewswire/ — Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level. Vigabatrin for Oral Solution, USP 500 mg has been found to have seal integrity issues allowing for powder leakage from the… Continue reading InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets
WORKS Announces New Executive Director
Extensive Search and Recruitment Process Led by Envision Consulting LOS ANGELES, Dec. 9, 2023 /PRNewswire/ — Women Organizing Resources Knowledge and Services (WORKS), a leading nonprofit specializing in affordable housing development in Los Angeles County, is delighted to announce the appointment of Monique Davis as its Chief Executive Officer, effective December 11, 2023. Continue Reading… Continue reading WORKS Announces New Executive Director
“MET GALA” FOR LATINOS GATHERED THE MOST IMPORTANT 500+ LATINOS IN THE COUNTRY
The exclusive event honored John Leguizamo, Daytime Emmy award-winning Raúl de Molina and Fashion Designer Anne Fontaine NEW YORK, Dec. 9, 2023 /PRNewswire/ — The We Are All Human Foundation on Dec. 7 commemorated its third Annual We Are All Human Gala—an evening dedicated to mobilizing support for the Hispanic community, accentuating the critical role Hispanics play… Continue reading “MET GALA” FOR LATINOS GATHERED THE MOST IMPORTANT 500+ LATINOS IN THE COUNTRY
New Hybrid Treatment Forces Cancer Cells to Starve
NEW YORK, Dec. 9, 2023 /PRNewswire/ — The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows. The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that remove germs. The cancerous cells build… Continue reading New Hybrid Treatment Forces Cancer Cells to Starve
AV-Comparatives veröffentlicht die Ergebnisse der 2023 Advanced Threat Protection-Tests für marktführende Cybersecurity-Produkte für Unternehmen und Verbraucher
AV-Comparatives hat die Ergebnisse des 2023 Advanced Threat Protection Tests für 15 Sicherheitsprodukte für Verbraucher und Unternehmen veröffentlicht „Die Tests zeigen, dass führende Sicherheitssoftware bei der Abwehr von gezielten Bedrohungen hervorragend abschneidet, wobei die Anbieter ihre Schutzmaßnahmen kontinuierlich verbessern.” – Andreas Clementi, Gründer und CEO, AV-Comparatives INNSBRUCK, Österreich, 27. November 2023 /PRNewswire/ — Der von… Continue reading AV-Comparatives veröffentlicht die Ergebnisse der 2023 Advanced Threat Protection-Tests für marktführende Cybersecurity-Produkte für Unternehmen und Verbraucher
VyOS Networks traz o VyOS Universal Router para a Equinix Network Edge e a Equinix Metal
POWAY, Califórnia, 9 de dezembro de 2023 /PRNewswire/ — A VyOS Networks anunciou que está trazendo o VyOS Universal Router para a Plataforma Equinix. Essa disponibilidade expandida visa dar suporte ao cenário de infraestrutura de rede, integrando as soluções de rede flexíveis e robustas da VyOS com o ecossistema de interconexão global da Equinix. O VyOS Universal… Continue reading VyOS Networks traz o VyOS Universal Router para a Equinix Network Edge e a Equinix Metal
Il Gruppo Menarini presenta a SABCS 2023 nuovi dati dallo studio clinico EMERALD su ORSERDU® (elacestrant) sulla sopravvivenza libera da progressione in sottogruppi clinicamente rilevanti di pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- con mutazioni di ESR1
Questa nuova analisi post-hoc dello studio di fase 3 EMERALD ha valutato elacestrant nella popolazione endocrino-sensibile (durata dell’inibitore delle CDK4/6 di almeno 12 mesi) affetta da carcinomi con mutazioni di ESR1. Questa analisi mostra un miglioramento clinicamente significativo nella sopravvivenza libera da progressione nei sottogruppi studiati, tra cui i pazienti con metastasi ossee, epatiche e/o polmonari, quelli con… Continue reading Il Gruppo Menarini presenta a SABCS 2023 nuovi dati dallo studio clinico EMERALD su ORSERDU® (elacestrant) sulla sopravvivenza libera da progressione in sottogruppi clinicamente rilevanti di pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- con mutazioni di ESR1